Skip to main content

Table 4 Clinical trials of midostaurin for AML therapy

From: FLT3 inhibitors in acute myeloid leukemia

Study agents

Other agents

Disease

Dose

No Pts

Response

Clinical trial

Reference

Midostaurin

Etoposide

Cytarabine

Relapsed

Refractory

50 mg bid

34

ORR 82.5%

CR 56.5%

Phase I

[47]

Midostaurin

ATRA

Chemotherapy

Relapsed

Refractory

25 mg/50 mg

twice daily

10

CR 22%

CRi 11%

Phase I

[48]

Midostaurin

Daunorubicin

Cytarabine

Untreated

50 mg twice daily

13

CR 92%

1-year OS 85%

Phase IB

[49]

     

2-year OS 62%

  
  1. OS overall survival, CR complete remission, CRi complete remission with incomplete count recovery, ATRA all-trans retinoic acid